An efficient drug to solve the problem of metastases associated to aggressive cancers, the main cause of cancer death.
Big Idea
R-nuucell is a spin-off of Faculdade de Ciências, Universidade de Lisboa. Its mission is to develop innovative chemotherapeutics to address unmet clinical needs, namely, to treat metastatic cancers. Its lead drug, ´Ru-Drug´, with a granted international patent, envisages the treatment of the Triple Negative Breast Cancer (TNBC) the most aggressive of all breast cancers, without cure, with a survival rate of 28% in 5 years. Its most recent in vivo studies in mice with TNBC, envisaging to consolidate the proof of concept, show that 6 treatments with our nontoxic innovative drug already cause the reduction of lung metastases in ~30%.
Activity Highlights
- InnoStars Awards, European Start-ups, Boost Program, 2021 (Granted)
- European Innovation Council Women TechEU, 2022 (Granted)
- First Place for the project “Rupharma”, in ScienceIN2Business Initiative promoted by TecLabs, 2015.
- “Young Investigator Award”, during the Conference “2nd European Conference on Smart Inorganic Polymers”, 2015.
- Scholarship by the programme “Fulbright grant for Portuguese Scholars and Researchers”.
- Private Investment from “Prodigy Bubble” beween 2017-2020 to financial support to test in vivo and international patent.
- Monetary Prize by the Royal Society of Chemistry Research Fund Grant, 2016.
- Thesis for PhD to represent the Portuguese Chemistry Society in the Conference “6th EFMC Young Medicinal Chemist Symposium”, 2019.
Team
Helena Garcia – Co-Founder & Board Member & Scientific Board; Andreia Valente – Co-Founder & Board Member& Scientific Board; Jorge Maia Alves – Board Member; Francisco Simões Rodrigues –General Manager; Rita Tomé Rocha –Advisory Board;
Portugal Ventures’ Investment Manager
